Tuberous Sclerosis Alliance To Analyze Natural History Database

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit

The Tuberous Sclerosis Alliance is the only national voluntary health organization in the United States dedicated to finding a cure for tuberous sclerosis complex (TSC) while improving the lives of those affected. In 1974, four mothers formed the organization to provide fellowship, generate awareness, pursue knowledge and offer hope to those who shared the common bond of TSC. TSC is a rare genetic disorder that causes tumors to form in vital organs, including the brain, eyes, skin, liver, lungs, heart and kidneys.  It is also the leading genetic cause of both autism and epilepsy.  TSC affects about 50,000 in the United States and more than 1 million worldwide.  Currently, there is no cure.  Since 2010, there have been two FDA-approved treatments to shrink tumors in the brain and kidneys of those with TSC, and promising research continues for additional therapies to improve the quality of daily life for every individual with TSC. For more information, visit

Original Press Release